CRP and type 2 diabetes mellitus: Circulating markers of inflammation, most notably high-sensitivity C-reactive protein, have been associated with adverse outcomes in a variety of clinical contexts.123–126 In the CARE trial,127 evidence of systemic inflammation, as measured by elevated CRP and serum amyloid A (SAA), was associated with an increased risk of recurrent coronary events after MI, but with a higher proportion of events in people with T2D.